Robert S. Epstein's most recent trade in Fate Therapeutics Inc was a trade of 87,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 87,900 | 87,900 | - | - | Stock Option (Right to Buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,272 | 57,718 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Robert S. Epstein | Director | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 20 May 2026 | 10,000 | 52,446 (0%) | 0% | 44.0 | 440,129 | Common Stock |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 05 May 2026 | 25,000 | 36,331 (0%) | 0% | 1.7 | 42,250 | Common Stock |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Sale of securities on an exchange or to another person at price $ 35.08 per share. | 01 Oct 2025 | 21,473 | 62,446 (0%) | 0% | 35.1 | 753,204 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.94 per share. | 01 Oct 2025 | 10,000 | 83,919 (0%) | 0% | 7.9 | 79,400 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 9,321 | 73,919 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | 21 May 2025 | 3,780 | 22,139 (0%) | 0% | 0 | Common Stock | ||
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 Jan 2025 | 20,000 | 64,598 (0%) | 0% | 8.0 | 160,800 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 15,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 12 Nov 2024 | 15,000 | 44,598 (0%) | 0% | 38.3 | 574,830 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 12 Nov 2024 | 15,000 | 59,598 (0%) | 0% | 8.0 | 120,600 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 44,598 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | 15 May 2024 | 2,622 | 18,306 (0%) | 0% | 0 | Common Stock | ||
| Illumina Inc | Robert S. Epstein | Director | 15 May 2024 | 612 | 15,684 (0%) | 0% | 115.0 | 70,386 | Common Stock | |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | 26 May 2023 | 1,532 | 16,296 (0%) | 0% | 0 | Common Stock | ||
| Illumina Inc | Robert S. Epstein | Director | 24 May 2023 | 7,600 | 14,764 (0%) | 0% | 71.1 | 540,284 | Common Stock | |
| Illumina Inc | Robert S. Epstein | Director | 24 May 2023 | 7,600 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Illumina Inc | Robert S. Epstein | Director | 24 May 2023 | 492 | 7,164 (0%) | 0% | 212.7 | 104,624 | Common Stock | |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock |